Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel ...
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option ...
CodeBreak 200 | Sotorasib | A Negligent trial that violated ...
This is from FDA’s ODAC document re Codebreak 200 trial. https://lnkd ...
ELCC 2023: Patient-reported outcomes from the CodeBreaK 200 phase 3 ...
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant ...
40 Patient-reported outcomes from the CodeBreaK 200 phase III trial ...
CodeBreaK 200 Data Continues to Support Sotorasib vs Docetaxel in KRAS ...
Additional findings from the CodeBreak 200 trial - OncoDaily
Unlocking NSCLC Treatments: A Deep Dive into CodeBreaK 200 - OncologyTube
CodeBreaK 200 & Sotorasib - by Timothée Olivier
Amgen Presents New Lumakras® (SOTORASIB) Codebreak 200 Cns Data at Asco ...
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of ...
CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in ...
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR|抗癌|多西|突变_新浪新闻
CodeBreak 200：治疗KRAS G12C突变晚期非小细胞肺癌患者，索托拉西布（Sotorasib）效果优于多西他赛！ - 知乎
(PDF) CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC ...
(PDF) CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR__财经头条
CodeBreaK 100 Study Design | LUMAKRAS® (sotorasib)
Estudio Codebreak 200: uso de sotorasib en cáncer de pulmón
CodeBreaK 100 Clinical Trial | LUMAKRAS® (sotorasib)
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients ...
CodeBreaK 300 Study Design | LUMAKRAS® (sotorasib) + Vectibix ...
CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C ...
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel ...
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code - PMC
CodeBreaK 200試験：KRASG12C変異陽性既治療NSCLCに対するソトラシブ : 呼吸器内科医
Full article: CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS ...
CodeBreaK 200研究：索托雷塞二线/后线治疗KRAS p.G12C突变的Ⅳ期NSCLC的III期临床研究_多西_患者_化疗
CodeBreaK 100/101 First report of safety and efficacy of sotorasib ...
2023 ESMO | CodeBreaK 300研究更新：Sotorasib能否绝处逢生？ - 知乎
CodeBreaK 101 at ASCO 2025: Sotorasib Triplet in KRAS CRC
CodeBreaK 200：Sotorasib治疗经治KRAS G12C 突变晚期 NSCLC的III 期试验 - 非小细胞肺癌 - 阳光肺科
CodeBreaK 200：Sotorasib治疗经治KRAS G12C 突变晚期 NSCLC的III 期试验 - 🥑非小细胞肺癌 - 阳光肺科
The fate of sotorasib: a regulatory failure potentially harming ...
Sotorasib versus docetaxel for previously treated non-small-cell lung ...
Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on ...
安进：FDA拒绝完全批准KRAS G12C，要求进行额外验证临床
国际大咖谈丨Dr.Gyawali点评CodeBreaK 200试验结果_腾讯新闻
Jacob Plieth on Twitter: "#Esmo22 discussant Natasha Leighl raises some ...
Sotorasib delays progression of advanced KRAS -mutant non-small cell ...
Sotorasib (Lumakras)
Sotorasib vs. Docetaxel for Previously Treated NSCLC With KRAS G12C ...
Metastatic NSCLC Treatment Efficacy | LUMAKRAS™ (sotorasib)
#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The ...
Sotorasib Versus Docetaxel for Previously Treated Patients With ...
Inicio
Sotorasib improves PFS in KRAS G12C-mutated NSCLC
从CodeBreak 200“梦的破碎”，看免疫治疗OS显著获益的重要性
2023 ASCO | NSCLC重磅研究抢“鲜”看|安全性|研究|肿瘤|疗效|-健康界
Targeted approaches in the first and later lines: KRASG12C, EGFR, HER2 ...
ソトラシブ、KRAS G12C変異陽性NSCLCのPFSを有意に延長（CodeBreaK-200）／ESMO2022｜医師向け医療ニュースはケアネット
蒙上阴影的Sotorasib （AMG510） - 知乎
J Clin Oncol：索托拉西布 vs 多西他赛治疗KRAS G12C突变晚期非小细胞肺癌（NSCLC）的颅内疗效（CodeBreaK ...
ESMO大会最新研究进展——肺癌如何抗耐药，防复发？|ESMO|EGFR|肺癌|耐药|-健康界
Sotorasib Has Not Broken the KRASG12C Enigma Code | LCTT
2023年 ELCC 靶向治疗重点一文速览-MedSci.cn
Sotorasib bei vielen Wirksamkeitsendpunkten überlegen gegenüber Doceta ...
KRAS突变非小细胞肺癌：sotorasib再现生存期优越性 - 知乎
JSMO 2023: Sotorasib versus Docetaxel for Previously Treated Non-Small ...
刚刚！2 : 10失败，ODAC认为由于系统性偏倚问题，CodeBreak 200主要终点PFS获益的可靠性不足医药新闻-ByDrug-一站式 ...
ESMO 2022: Sotorasib versus docetaxel for previously treated non-small ...
10月ODAC预告 | Sotorasib是否「真正」破解了KRAS G12C的摩斯密码？医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
ELCC 2023丨CodeBreaK 200：Sotorasib改善了KRAS g12c突变NSCLC经治患者的生活质量-肿瘤瞭望
CPCNP KRAS G12C: Sotorasib alcanza objetivo primario de SLP, estudio ...
Omnihealth Practice | Sotorasib demonstrates consistent clinical ...
安进KRAS抑制剂：III期确证性研究PFS获益可靠性遭FDA委员会质疑医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
【爱肠学院】CodeBreaK 300研究：Sotorasib+帕尼单抗在化疗难治性KRAS G12C突变型转移性结直肠癌的探索医药新闻 ...
Porter Explores Data for Sotorasib in KRAS-Mutated NSCLC
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A ...
Lung Cancer - For healthcare professionals only
首个KRAS抑制剂-索托拉西布或将面临退市！ - MedFind
・CodeBreaK 200試験、アジア（日韓）人サブグループ解析 - 大分で肺癌診療
ESMO大會最新研究進展——肺癌如何抗耐藥，防復發？ - 每日頭條
00616-2/asset/95295b9b-dae0-49a1-af57-e210884235e2/main.assets/gr1_lrg.jpg)
.png)
